Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant CancersHusain Yar Khan, Asfar S. Azmi, Misako Nagasaka et al.|Cancer Research Communications|2022Cited by 27
Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation TherapyHusain Yar Khan, Asfar S. Azmi, Mandana Kamgar et al.|Advances in Radiation Oncology|2022Cited by 20
Abstract CT080: A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinomaMandana Kamgar, William A. Hall, Husain Yar Khan et al.|Cancer Research|2024Cited by 3
Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancersHusain Yar Khan, Asfar S. Azmi, Yiwei Li et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1
Data from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant CancersHusain Yar Khan, Asfar S. Azmi, Misako Nagasaka et al.|Unknown|2023Cited by 0